Loeb Cuts Kenvue Stake 64%; Johnson & Johnson Acquires Atraverse, Lists Drugs on TrumpRx
Daniel Loeb reduced his Kenvue stake by 64% to 3.25 million shares in Q4 2025 as Kenvue plans a 3.5% workforce cut and $250 million in 2026 charges. Johnson & Johnson will list four prescription drugs on TrumpRx and acquire Atraverse Medical’s HOTWIRE system in Q2 2026.
1. Kenvue Stake Reduction
Daniel Loeb trimmed his position in Kenvue by 64% in Q4 2025, reducing holdings from 9.0 million to 3.25 million shares. Kenvue is preparing a 3.5% workforce reduction and expects $250 million in charges during 2026 as it progresses toward a $48.7 billion enterprise valuation deal with Kimberly-Clark anticipated to close in H2 2026.
2. TrumpRx Drug Listings
Johnson & Johnson will begin listing four of its prescription medications on the TrumpRx platform, expanding patient access through the administration’s drug-pricing website. This move marks a direct-to-consumer push designed to boost visibility and pricing competitiveness for key J&J products.
3. Atraverse Medical Acquisition
Johnson & Johnson agreed to acquire Atraverse Medical, the developer of the FDA-cleared HOTWIRE Transseptal Access System used in nearly 3,000 left-heart access procedures. The deal, expected to close in Q2 2026 pending customary approvals, will strengthen J&J’s cardiac ablation portfolio with advanced radiofrequency guidewire technology.